Literature DB >> 12499234

Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae.

Glen T Hansen, Kelli Metzler, Karl Drlica, Joseph M Blondeau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499234      PMCID： PMC149038          DOI： 10.1128/AAC.47.1.440-441.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

Review 2.  What have we learned from pharmacokinetic and pharmacodynamic theories?

Authors:  J J Schentag; K K Gilliland; J A Paladino
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

3.  Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae.

Authors:  F J Schmitz; M Boos; S Mayer; D Hafner; H Jagusch; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

5.  Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.

Authors:  J K Thomas; A Forrest; S M Bhavnani; J M Hyatt; A Cheng; C H Ballow; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 7.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

Review 8.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

9.  Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy.

Authors:  C Urban; N Rahman; X Zhao; N Mariano; S Segal-Maurer; K Drlica; J J Rahal
Journal:  J Infect Dis       Date:  2001-08-09       Impact factor: 5.226

10.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

Authors:  P L Ho; R W Yung; D N Tsang; T L Que; M Ho; W H Seto; T K Ng; W C Yam; W W Ng
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790
View more
  9 in total

Review 1.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

2.  Low correlation between MIC and mutant prevention concentration.

Authors:  Karl Drlica; Xilin Zhao; Joseph M Blondeau; Christine Hesje
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Pamela McGhee; Glenn A Pankuch; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

4.  Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.

Authors:  E Azoulay-Dupuis; J P Bédos; J Mohler; P Moine; C Cherbuliez; G Peytavin; B Fantin; T Köhler
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae.

Authors:  Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  J Antimicrob Chemother       Date:  2012-11-20       Impact factor: 5.790

6.  Mutant prevention concentrations of four carbapenems against gram-negative rods.

Authors:  Kim Credito; Klaudia Kosowska-Shick; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

7.  The role of RamA on the development of ciprofloxacin resistance in Salmonella enterica serovar Typhimurium.

Authors:  Yawei Sun; Menghong Dai; Haihong Hao; Yulian Wang; Lingli Huang; Yassir A Almofti; Zhenli Liu; Zonghui Yuan
Journal:  PLoS One       Date:  2011-08-12       Impact factor: 3.240

Review 8.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 9.  Current management of acute bacterial rhinosinusitis and the role of moxifloxacin.

Authors:  Jack B Anon
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.